Search

Your search keyword '"Ibbadu, Guido Ferreri"' showing total 14 results
Start Over Author "Ibbadu, Guido Ferreri"
14 results on '"Ibbadu, Guido Ferreri"'

8. Corrigendum to “Anticonvulsant effects of carbenoxolone in genetically epilepsy prone rats (GEPRs)”[Neuropharmacology 47 (2004) 1205-1216]

Author

Gareri, Pietro, primary, Condorelli, Daniele, additional, Belluardo, Natale, additional, Russo, Emilio, additional, Loiacono, Antonella, additional, Barresi, Vincenza, additional, Trovato-Salinaro, Angela, additional, Mirone, Melita B., additional, Ibbadu, Guido Ferreri, additional, and De Sarro, Giovambattista, additional

Published
2009
Full Text
View/download PDF

9. Corrigendum to “Antiabsence effects of carbenoxolone in two genetic animal models of absence epilepsy (WAG/Rij rats and lh/lh mice)”

Author

Gareri, Pietro, primary, Condorelli, Daniele, additional, Belluardo, Natale, additional, Citraro, Rita, additional, Barresi, Vincenza, additional, Trovato-Salinaro, Angela, additional, Mudo‘, Giuseppa, additional, Ibbadu, Guido Ferreri, additional, Russo, Emilio, additional, and De Sarro, Giovambattista, additional

Published
2009
Full Text
View/download PDF

13. Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa.

Author

Siniscalchi A, Gallelli L, Mercuri NB, Ibbadu GF, and De Sarro G

Subjects
Antiparkinson Agents therapeutic use, Folic Acid administration & dosage, Homocysteine genetics, Homocysteine metabolism, Levodopa therapeutic use, Polymorphism, Genetic, Riboflavin administration & dosage, Vitamin B 6 administration & dosage, Antiparkinson Agents adverse effects, Homocysteine blood, Levodopa adverse effects, Life Style, Parkinson Disease blood, Parkinson Disease drug therapy
Abstract

Many papers documented that Parkinson's disease (PD) patients treated with levodopa (L-dopa) shows elevated plasma homocysteine (Hcy) levels. Several lifestyle factors are able to influence plasma Hcy levels. We review the evidence that L-dopa therapy is related with an increase in plasma Hcy levels and that several behaviours could be able to cause changes in plasma Hcy concentrations. Therefore, there are reasons to suggest that a healthy lifestyle lowering Hcy may prevent this potential iatrogenic complication during L-dopa therapy. Moreover, at present, no controlled prospective studies have evaluated this phenomenon.

Published
2006
Full Text
View/download PDF

14. AMPA receptor antagonists as potential anticonvulsant drugs.

Author

De Sarro G, Gitto R, Russo E, Ibbadu GF, Barreca ML, De Luca L, and Chimirri A

Subjects
Animals, Anticonvulsants therapeutic use, Binding, Competitive drug effects, Epilepsy drug therapy, Humans, Anticonvulsants pharmacology, Receptors, AMPA antagonists & inhibitors
Abstract

Over the last years alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptors (AMPARs) have been intensively studied owing to their crucial role in physiological and pathological processes. Efforts targeting AMPAR have been focused on identification of ligands as potential therapeutic agents useful in the prevention and treatment of a variety of neurological and non-neurological diseases. In particular, extensive work was addressed to the discovery of selective antagonists some of which proved to be potent anticonvulsant agents.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results